Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.33 Billion DKK | -212.5% |
| 2022 | 1.18 Billion DKK | 118.93% |
| 2021 | 540.77 Million DKK | 192.98% |
| 2020 | 184.57 Million DKK | -87.97% |
| 2019 | 1.53 Billion DKK | 303.97% |
| 2018 | 379.83 Million DKK | 218.14% |
| 2017 | 119.39 Million DKK | 114.53% |
| 2016 | -821.74 Million DKK | -141.14% |
| 2015 | -340.77 Million DKK | 6.17% |
| 2014 | -363.17 Million DKK | -36.29% |
| 2013 | -266.48 Million DKK | -0.88% |
| 2012 | -264.16 Million DKK | -52.74% |
| 2011 | -172.95 Million DKK | -8.1% |
| 2010 | -159.98 Million DKK | -97.63% |
| 2009 | -80.95 Million DKK | 85.79% |
| 2008 | -569.77 Million DKK | -5.72% |
| 2007 | -538.94 Million DKK | -642.48% |
| 2006 | 99.34 Million DKK | 393.31% |
| 2005 | -33.87 Million DKK | 58.02% |
| 2004 | -80.69 Million DKK | 59.47% |
| 2003 | -199.11 Million DKK | -112.91% |
| 2002 | -93.51 Million DKK | -245.43% |
| 2001 | -27.07 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -691.79 Million DKK | 4.87% |
| 2024 Q1 | -727.22 Million DKK | 45.4% |
| 2023 Q4 | -1.33 Billion DKK | -43.82% |
| 2023 Q2 | 96.32 Million DKK | 117.89% |
| 2023 Q1 | -538.6 Million DKK | -145.49% |
| 2023 FY | -1.33 Billion DKK | -212.5% |
| 2023 Q3 | -926.09 Million DKK | -1061.38% |
| 2022 Q1 | 571.66 Million DKK | 5.71% |
| 2022 FY | 1.18 Billion DKK | 118.93% |
| 2022 Q4 | 1.18 Billion DKK | 45.96% |
| 2022 Q3 | 811.14 Million DKK | -30.08% |
| 2022 Q2 | 1.16 Billion DKK | 102.93% |
| 2021 Q3 | 590.59 Million DKK | -1.8% |
| 2021 Q1 | 239.43 Million DKK | 29.72% |
| 2021 Q2 | 601.44 Million DKK | 151.19% |
| 2021 FY | 540.77 Million DKK | 192.98% |
| 2021 Q4 | 540.77 Million DKK | -8.44% |
| 2020 Q4 | 184.57 Million DKK | 318.44% |
| 2020 FY | 184.57 Million DKK | -87.97% |
| 2020 Q1 | -979.34 Million DKK | -163.83% |
| 2020 Q2 | 105.22 Million DKK | 110.74% |
| 2020 Q3 | -84.5 Million DKK | -180.3% |
| 2019 Q2 | 350.75 Million DKK | 6.82% |
| 2019 Q4 | 1.53 Billion DKK | 330.05% |
| 2019 Q3 | 356.79 Million DKK | 1.72% |
| 2019 FY | 1.53 Billion DKK | 303.97% |
| 2019 Q1 | 328.34 Million DKK | -13.55% |
| 2018 Q1 | 361.91 Million DKK | 203.14% |
| 2018 Q3 | 303.7 Million DKK | -40.4% |
| 2018 Q4 | 379.83 Million DKK | 25.06% |
| 2018 FY | 379.83 Million DKK | 218.14% |
| 2018 Q2 | 509.61 Million DKK | 40.81% |
| 2017 Q2 | -327.34 Million DKK | 66.39% |
| 2017 Q4 | 119.39 Million DKK | 127.83% |
| 2017 FY | 119.39 Million DKK | 114.53% |
| 2017 Q1 | -973.85 Million DKK | -18.51% |
| 2017 Q3 | -428.93 Million DKK | -31.03% |
| 2016 Q3 | -176.81 Million DKK | 58.58% |
| 2016 FY | -821.74 Million DKK | -141.14% |
| 2016 Q4 | -821.74 Million DKK | -364.74% |
| 2016 Q2 | -426.9 Million DKK | -180.49% |
| 2016 Q1 | -152.2 Million DKK | 55.34% |
| 2015 Q4 | -340.77 Million DKK | 20.49% |
| 2015 Q1 | -984.6 Million DKK | -171.11% |
| 2015 Q2 | -471 Million DKK | 52.16% |
| 2015 FY | -340.77 Million DKK | 6.17% |
| 2015 Q3 | -428.57 Million DKK | 9.01% |
| 2014 FY | -363.17 Million DKK | -36.29% |
| 2014 Q1 | -149 Million DKK | 44.09% |
| 2014 Q2 | -38.2 Million DKK | 74.36% |
| 2014 Q3 | -68.5 Million DKK | -79.32% |
| 2014 Q4 | -363.17 Million DKK | -430.19% |
| 2013 Q3 | -65.5 Million DKK | 68.63% |
| 2013 FY | -266.48 Million DKK | -0.88% |
| 2013 Q1 | -50.8 Million DKK | 80.77% |
| 2013 Q2 | -208.8 Million DKK | -311.02% |
| 2013 Q4 | -266.48 Million DKK | -306.85% |
| 2012 Q1 | -158.4 Million DKK | 8.41% |
| 2012 Q4 | -264.16 Million DKK | -51.99% |
| 2012 Q3 | -173.8 Million DKK | -27.98% |
| 2012 FY | -264.16 Million DKK | -52.74% |
| 2012 Q2 | -135.8 Million DKK | 14.27% |
| 2011 Q2 | 25.3 Million DKK | -64.62% |
| 2011 Q1 | 71.5 Million DKK | 144.69% |
| 2011 Q4 | -172.95 Million DKK | -199.4% |
| 2011 Q3 | 174 Million DKK | 587.75% |
| 2011 FY | -172.95 Million DKK | -8.1% |
| 2010 Q1 | -86.1 Million DKK | -6.36% |
| 2010 Q4 | -159.98 Million DKK | -1528.45% |
| 2010 Q3 | 11.2 Million DKK | -32.12% |
| 2010 FY | -159.98 Million DKK | -97.63% |
| 2010 Q2 | 16.5 Million DKK | 119.16% |
| 2009 Q4 | -80.95 Million DKK | 0.0% |
| 2009 FY | -80.95 Million DKK | 85.79% |
| 2008 FY | -569.77 Million DKK | -5.72% |
| 2007 FY | -538.94 Million DKK | -642.48% |
| 2006 FY | 99.34 Million DKK | 393.31% |
| 2005 FY | -33.87 Million DKK | 58.02% |
| 2004 FY | -80.69 Million DKK | 59.47% |
| 2003 FY | -199.11 Million DKK | -112.91% |
| 2002 FY | -93.51 Million DKK | -245.43% |
| 2001 FY | -27.07 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 291 Million DKK | 557.709% |
| Genmab A/S | -14.09 Billion DKK | 90.552% |
| Gubra A/S | 18.03 Million DKK | 7484.034% |
| Novo Nordisk A/S | 12.61 Billion DKK | 110.559% |
| Orphazyme A/S | -11.26 Million DKK | -11719.434% |
| Pharma Equity Group A/S | 25.99 Million DKK | 5224.786% |
| Zealand Pharma A/S | -249.03 Million DKK | -434.835% |